199 related articles for article (PubMed ID: 29192951)
1. First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - three-month results.
Gil RJ; Bil J; Kern A; Pawłowski T
Kardiol Pol; 2018; 76(2):464-470. PubMed ID: 29192951
[TBL] [Abstract][Full Text] [Related]
2. First-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BiOSS LIM® Registry.
Gil RJ; Bil J; Vassiliev D; Iñigo Garcia LA
J Interv Cardiol; 2015 Feb; 28(1):51-60. PubMed ID: 25689548
[TBL] [Abstract][Full Text] [Related]
3. First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.
Gil RJ; Vassiliev D; Michałek A; Kern A; Formuszewicz R; Dobrzycki S; Lesiak M; Wójcik J; Kardaszewicz P; Lekston A
Kardiol Pol; 2012; 70(1):45-52. PubMed ID: 22267425
[TBL] [Abstract][Full Text] [Related]
4. Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.
Gil RJ; Bil J; Grundeken MJ; Iñigo Garcia LA; Vassilev D; Kern A; Pawłowski T; Wykrzykowska JJ; Serruys PW
EuroIntervention; 2016 Nov; 12(10):1246-1254. PubMed ID: 26465375
[TBL] [Abstract][Full Text] [Related]
5. Dedicated bifurcation paclitaxel-eluting stent BiOSS Expert® in the treatment of distal left main stem stenosis.
Bil J; Gil RJ; Vassilev D; Rzezak J; Kulawik T; Pawlowski T
J Interv Cardiol; 2014 Jun; 27(3):242-51. PubMed ID: 24708143
[TBL] [Abstract][Full Text] [Related]
6. Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry.
Gil RJ; Kern A; Pawłowski T; Bil J
Arch Med Sci; 2023; 19(2):324-330. PubMed ID: 37034511
[TBL] [Abstract][Full Text] [Related]
7. Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.
Kern A; Gil RJ; Bojko K; Rzeszowski B; Bednarski K; Górny J; Bil J
Cardiol J; 2018; 25(2):188-195. PubMed ID: 28714525
[TBL] [Abstract][Full Text] [Related]
8. Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.
Gil RJ; Bil J; Grundeken MJ; Kern A; Iñigo Garcia LA; Vassilev D; Pawłowski T; Formuszewicz R; Dobrzycki S; Wykrzykowska JJ; Serruys PW
EuroIntervention; 2016 Dec; 12(11):e1404-e1412. PubMed ID: 26600564
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies.
Gil RJ; Bil J; Kern A; Iñigo Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Segiet A
Cardiol J; 2018; 25(3):308-316. PubMed ID: 28840591
[TBL] [Abstract][Full Text] [Related]
10. Dedicated paclitaxel-eluting bifurcation stent BiOSS® (bifurcation optimisation stent system): 12-month results from a prospective registry of consecutive all-comers population.
Gil RJ; Vassilev D; Michalek A; Kern A; Formuszewicz R; Dobrzycki S; Wójcik J; Lesiak M; Kardaszewicz P; Lekston A
EuroIntervention; 2012 Jul; 8(3):316-24. PubMed ID: 22829507
[TBL] [Abstract][Full Text] [Related]
11. Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies.
Gil RJ; Bil J; Kern A; Iñigo-Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Mehran R
Cardiovasc Ther; 2020; 2020():6760205. PubMed ID: 32411301
[TBL] [Abstract][Full Text] [Related]
12. The approach to coronary bifurcation treatment and its outcomes in Poland: The single center experience.
Kern A; Gil RJ; Bojko K; Rzeszowski B; Jalali R; Górny J; Bil J
Cardiol J; 2017; 24(6):589-596. PubMed ID: 28541601
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of a dedicated bifurcation stent system.
Sivalingam J; Mazhar MW; Chaddad RA; Fouladvand F; Cortese B
Cardiovasc Revasc Med; 2024 Feb; 59():21-26. PubMed ID: 37666716
[TBL] [Abstract][Full Text] [Related]
14. BiOSS LIM C: thin-strut cobalt-chromium version of the dedicated bifurcation stent.
Gil RJ; Bil J; Kaczynski M; Milewski KP
Expert Rev Med Devices; 2017 Apr; 14(4):279-284. PubMed ID: 28394644
[TBL] [Abstract][Full Text] [Related]
15. Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.
Gil RJ; Bil J; Džavík V; Vassilev D; Kern A; Formuszewicz R; Zalewska-Adamiec M; Dobrzycki S
Can J Cardiol; 2015 May; 31(5):671-8. PubMed ID: 25828372
[TBL] [Abstract][Full Text] [Related]
16. Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study.
Asano T; Kogame N; Onuma Y; Modolo R; Chichareon P; Lefèvre T; Legutko J; Digne F; Morel MA; Serruys PW; Gil RJ
EuroIntervention; 2020 Oct; 16(8):654-662. PubMed ID: 31543500
[TBL] [Abstract][Full Text] [Related]
17. 12-month intravascular ultrasound observations from BiOSS® first-in-man studies.
Gil RJ; Bil J; Costa RA; Gil KE; Vassiliev D
Int J Cardiovasc Imaging; 2016 Sep; 32(9):1339-1347. PubMed ID: 27314841
[TBL] [Abstract][Full Text] [Related]
18. Acute and long-term results of percutaneous coronary intervention of bifurcation lesions with the dedicated Bioss Lim C stent: the Italian BIfurcation Observational Spontaneous Study (IBIOSS).
Briguori C; Capodanno D; Contarini M; Donahue ME; Evola S; Garro N; Greco F; LA Manna A; Murè P; Nicosia A; Migliore G; Sacchetta G; Signore N; Tamburino C; Vizzari G; Biondi-Zoccai G
Minerva Med; 2024 Apr; 115(2):171-177. PubMed ID: 38536058
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent.
Gil RJ; Pawłowski T; Legutko J; Lesiak M; Witkowski A; Gąsior M; Kern A; Bil J
Medicine (Baltimore); 2019 Apr; 98(14):e15106. PubMed ID: 30946377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
